How to buy Precision BioSciences stock | 9.54

Precision BioSciences, Inc is a biotechnology business based in the US. Precision BioSciences shares (DTIL) are listed on the NASDAQ and all prices are listed in US Dollars. Precision BioSciences employs 220 staff and has a trailing 12-month revenue of around USD$19.5 million.

How to buy shares in Precision BioSciences

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Precision BioSciences. Find the stock by name or ticker symbol: DTIL. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Precision BioSciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$9.54, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Precision BioSciences, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Precision BioSciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Precision BioSciences's share price?

Since the stock market crash in March caused by coronavirus, Precision BioSciences's share price has had significant positive movement.

Its last market close was USD$9.54, which is 16.04% up on its pre-crash value of USD$8.01 and 91.18% up on the lowest point reached during the March crash when the shares fell as low as USD$4.99.

If you had bought USD$1,000 worth of Precision BioSciences shares at the start of February 2020, those shares would have been worth USD$688.54 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,160.54.

Precision BioSciences share price

Use our graph to track the performance of DTIL stocks over time.

Precision BioSciences shares at a glance

• Key figures

Information last updated 2020-10-19.

Latest market close	USD$9.54
52-week range	USD$4.6 - USD$23.6702
50-day moving average	USD$6.0141
200-day moving average	USD$6.9362
Wall St. target price	USD$17.57
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.124

Buy Precision BioSciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Precision BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Precision BioSciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Precision BioSciences price performance over time

Historical closes compared with the close of $9.54 from 2020-11-16

1 week (2020-11-20)	-11.01%
1 month (2020-10-30)	51.19%
3 months (2020-08-28)	70.36%
6 months (2020-05-29)	36.09%

1 year (2019-11-29)	-46.31%
2 years (2018-11-26)	N/A
3 years (2017-11-26)	N/A
5 years (2015-11-26)	N/A

Precision BioSciences financials

Revenue TTM	USD$19.5 million
Gross profit TTM	USD$22.2 million
Return on assets TTM	-28.54%
Return on equity TTM	-77.97%
Profit margin	0%
Book value	$1.641
Market capitalisation	USD$357 million

TTM: trailing 12 months

Shorting Precision BioSciences shares

There are currently 2.8 million Precision BioSciences shares held short by investors – that's known as Precision BioSciences's "short interest". This figure is 29.8% up from 2.2 million last month.

There are a few different ways that this level of interest in shorting Precision BioSciences shares can be evaluated.

Precision BioSciences's "short interest ratio" (SIR)

Precision BioSciences's "short interest ratio" (SIR) is the quantity of Precision BioSciences shares currently shorted divided by the average quantity of Precision BioSciences shares traded daily (recently around 866245.0617284). Precision BioSciences's SIR currently stands at 3.24. In other words for every 100,000 Precision BioSciences shares traded daily on the market, roughly 3240 shares are currently held short.

However Precision BioSciences's short interest can also be evaluated against the total number of Precision BioSciences shares, or, against the total number of tradable Precision BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Precision BioSciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Precision BioSciences shares in existence, roughly 50 shares are currently held short) or 0.0608% of the tradable shares (for every 100,000 tradable Precision BioSciences shares, roughly 61 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Precision BioSciences.

Find out more about how you can short Precision BioSciences stock.

Precision BioSciences share dividends

We're not expecting Precision BioSciences to pay a dividend over the next 12 months.

Precision BioSciences overview

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

Frequently asked questions

• What percentage of Precision BioSciences is owned by insiders or institutions?

  Currently 12.062% of Precision BioSciences shares are held by insiders and 54.998% by institutions.

• How many people work for Precision BioSciences?

  Latest data suggests 220 work at Precision BioSciences.

• When does the fiscal year end for Precision BioSciences?

  Precision BioSciences's fiscal year ends in December.

• Where is Precision BioSciences based?

  Precision BioSciences's address is: Dibrell Building, Durham, NC, United States, 27701

• What is Precision BioSciences's CUSIP number?

  Precision BioSciences's Committee on Uniform Securities Identification Procedures number is: 74019P108